Combined targeted therapy and immunotherapy for cancer treatment

Although targeted therapies and immunotherapies have been effective against several malignancies, the respective monotherapies are limited by low and/or short-term responses. Specific inhibitors of oncogenic signaling pathways and tumor-associated angiogenesis can activate the anti-tumor immune resp...

Full description

Saved in:
Bibliographic Details
Published in:World journal of clinical cases 2021-09, Vol.9 (26), p.7643-7652
Main Authors: Guo, Cheng-Xiang, Huang, Xing, Xu, Jian, Zhang, Xiao-Zhen, Shen, Yi-Nan, Liang, Ting-Bo, Bai, Xue-Li
Format: Article
Language:English
Subjects:
Minireviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although targeted therapies and immunotherapies have been effective against several malignancies, the respective monotherapies are limited by low and/or short-term responses. Specific inhibitors of oncogenic signaling pathways and tumor-associated angiogenesis can activate the anti-tumor immune responses by increasing tumor antigen presentation or intratumor T cell infiltration. Additional insights into the effects and mechanisms of targeted therapies on the induction of anti-tumor immunity will facilitate development of rational and effective combination strategies that synergize rapid tumor regression and durable response. In this review, we have summarized the recent combinations of targeted therapies and immunotherapies, along with the associated clinical challenges.
ISSN:2307-8960
2307-8960
DOI:10.12998/wjcc.v9.i26.7643